Bot Detector
IJPC Seal
Download FREE Sample Issue or Article
LEARN MORE
Subscribe Today
A subscription to IJPC provides on-line access to full-text, full-color, printable PDF copies of your subscribed issues, individual articles, and purchased archives.

Transdermal Methimazole in the Treatment of 16 Cats with Hyperthyroidism

Author(s):  Wingate Gary

Issue:  Sep/Oct 2002 - Veterinary Compounding
View All Articles in Issue

Page(s):  344-345

Transdermal Methimazole in the Treatment of 16 Cats with Hyperthyroidism Page 1
Transdermal Methimazole in the Treatment of 16 Cats with Hyperthyroidism Page 2

Download in electronic PDF format for $75

Abstract:  The efficacy of transdermal methimazole in 16 cats with hyperthyroidism was evaluated. During the 2-year study period, 15 of the 16 treated cats exhibited a significant decrease in serum T4 value, and in 1 cat the serum T4 level increased. The mean total dose, which was administered once or twice daily, was 6.53 mg/day (range, 5 to 12.5 mg). An initial recheck of the T4 level was conducted after an average of 7.4 weeks (range, 4 to 38 wk) of treatment with transdermal methimazole. The cats that responded to therapy showed a mean reduction in the T4 level from 10.82 mg/dL (range, 4.2 to 24 mg/dL) to 2.76 mg/dL (range, 0.3 to 5.2 mg/dL). The only adverse effect of treatment (an increase in the blood urea nitrogen [BUN] level) developed in only one cat (6%) within 30 days of the initiation of therapy; that patient was scheduled to undergo reevaluation of the BUN level after 2 months. The increase in the BUN level in that cat, which was 16 years of age, was probably due to an unmasking of preexisting senile renal dysfunction rather than treatment-induced toxicity. The most common symptoms of the 16 cats studied before they underwent treatment with transdermal methimazole were weight loss, which was associated with increased appetite in some cats, and heart murmur. Other symptoms included vomiting, vocalization, and lethargy. The results of the study indicate that transdermal methimazole is effective in blocking excess thyroid hormone secretion in most cats and that it is a relatively safe antithyroid medication therapy for use in cats.

Related Keywords: Feline hyperthyroidism, use of methimazole, Hyperthyroidism, methimazole use in cats, Transdermal methimazole, use in feline hyperthyroidism

Related Categories: VETERINARY

Printer-Friendly Version



Related Articles from IJPC
Title/Author
(Click for Abstract / Details / Purchase)
Issue/​Page
View/Buy
Transdermal Methimazole in the Treatment of 16 Cats with Hyperthyroidism
Wingate Gary
Sep/Oct 2002
Pg. 344-345

Veterinary Transdermal Medications: A to Z
Davidson Gigi S
Mar/Apr 2003
Pg. 106-113

Understanding Feline Hyperthyroidism
Davidson Gigi S
Sep/Oct 2003
Pg. 345-347

Evaluating Transdermal Medication Forms for Veterinary Patients, Part 3: Methimazole
Davidson Gigi S
Jul/Aug 2001
Pg. 282-283

Stability of Methimazole in Poloxamer Lecithin Organogel to Determine Beyond-Use Date
Pignato Alyssa
, Pankaskie Marvin, Birnie Christine
Nov/Dec 2010
Pg. 522-525

Methimazole 5 mg/0.1 mL in Pluronic Lecithin Organogel Gel, Veterinary
Allen Loyd V Jr
Jan/Feb 2019
Pg. 56

Methimazole 10-mg/mL Oral Liquid, Veterinary
Allen Loyd V Jr
May/Jun 2005
Pg. 229

Transdermal Amlodipine Besylate in Lipoderm for the Treatment of Feline Hypertension: A Report of Two Cases
Mixon William
, Helms Scott R
Sep/Oct 2008
Pg. 392-397

Feline Ophthalmic Disease: Feline Herpesvirus and Systemic Hypertension
Davidson Michael G
Mar/Apr 2001
Pg. 92-94

Drug Therapy for Acute and Chronic Pain in the Cat
Lascelles B Duncan
Sep/Oct 2002
Pg. 338-343

Case Report: Management of Secondary Hypertension in a Feline with the Use of Transdermal Prazosin
Rudner Shara
, Browne Paul
Nov/Dec 2010
Pg. 488-491

Compounding Transdermal Medication for Feline Patients
Eichstadt Lauren R
Jul/Aug 2016
Pg. 271-274

Unlicensed Transdermal Medications in Feline Patients: Three Case Reports
Urwin Craig
, Jean Linda, Carvalho Maria, Robson-Laws Michael
Nov/Dec 2022
Pg. 468-472

Feline Transdermal Formulation Considerations
Forsythe Lauren Eichstadt
Nov/Dec 2017
Pg. 446-452

Case Report: Transdermal Fluoxetine as Therapy for Feline Anxiety
Fields Shannon W
Nov/Dec 2006
Pg. 418

Methimazole 5 mg/0.1 mL in PLO (Vet)
Allen Loyd V Jr
May/Jun 2003
Pg. 183

Methimazole 5-mg/0.1-mL in Pluronic Lecithin Organogel
Allen Loyd V Jr
Mar/Apr 2001
Pg. 132

Feline Urologic Syndrome and Diet Formulation
Long Scott F
Sep/Oct 1999
Pg. 366-367

Evaluation of Compounded Transdermal Analgesic Formulations Using the Franz Finite Dose Model
Baneshi Marzieh
, Tyagi Deependra, Panneerselvam Ezilrani, MacKenzie Graham, Coleman Johngary, Zhang Shine X
Sep/Oct 2023
Pg. 424-430

Sensitization Therapy for Warts
Kuntz Rachael
Jul/Aug 2003
Pg. 266-270

Return to Top